Rakuten Medical
Rakuten Medical Raises $100M Series F | Photoimmunotherapy Cancer Treatment
Rakuten Medical Closes $100M for Cancer Treatment
Rakuten Medical, developing photoimmunotherapy treatments for cancer, has raised $100 million in Series F funding led by TaiAx.
Key Highlights
- Currently in global Phase 3 trial
- Novel photoimmunotherapy approach
- Late-stage clinical development
Company Overview
Rakuten Medical is developing a precision cancer treatment using photoimmunotherapy that selectively destroys cancer cells while preserving healthy tissue.
Company Info
Investors (2)
Share
Related Reports
Wabi Raises $55M at $1.25B Valuation in IVP-Led Funding
Wabi announced $55 million in funding led by IVP at a $1.25 billion valuation, which it said will support continued product development and expansion.
StimCardio Raises $30M Series A for Wearable AF Therapeutic
StimCardio announced the closing of an oversubscribed $30 million Series A led by Metis Medtech, expected to fund the company through its planned NeuroPulse 2 pivotal study and preparation for an FDA De Novo submission.
Casap Raises $56M Series B for AI Agents in Financial Services
Casap raised a $56 million Series B led by Base10 Partners, with Experian and Synchrony participating, to advance its AI agent platform for financial services.
Turn your sales ideas into reality today
Pick a plan and go live today. Change or cancel any time.
Get started


